References
- 1. OZEN S, KONE-PAUT I, GÜL A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2007; 47(1):115–20.
- 2. PROCOPIO V, MANTI S, BIANCO G, CONTI G, ROMEO A, MAIMONE F, et al. Genotype-phenotype correlation in FMF patients: A “non classic” recessive autosomal or “atypical” dominant autosomal inheritance? Gene. 2018; 641:279–86.
- 3. YANG L, LI Y, DING Y, CHOI K-S, KAZIM AL, ZHANG Y. Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. J Biol Chem. 2013; 288(4):2365–75.
- 4. SEZER U, ERCIYAS K, ÜSTÜN K, PEHLIVAN Y, ZIYA ŞENYURT S, AKSOY N, et al. Effect of Chronic Periodontitis on Oxidative Status in Patients With Rheumatoid Arthritis. J Periodontol. 2013; 84(6):785–92.
- 5. MENG X, GRÖTSCH B, LUO Y, KNAUP KX, WIESENER MS, CHEN X-X, et al. Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease. Nat Commun. 2018; 9(1):251.
- 6. PENG J, SHEN S, WANG J, JIANG H, WANG Y. Ηypoxia-inducible factor 1-α promotes colon cell proliferation and migration by upregulating AMPK-related protein kinase 5 under hypoxic conditions. Oncol Lett. 2018; 15(3):3639–3645.
- 7. WU J, CUI H, ZHU Z, WANG L, LI H, WANG D. Effect of HIF1α on Foxp3 expression in CD4 + CD25 − T lymphocytes. Microbiol Immunol. 2014; 58(7):409–15.
- 8. PRAS E, LIVNEH A, BALOW JE JR, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever, Am J Med Genet. 1998; 75: 216–9
- 9. ARE VN, KUMAR A, KUMAR S, GOYAL VD, GHOSH B, BHATNAGAR D, et al. Crystal structure and biochemical investigations reveal novel mode of substrate selectivity and illuminate substrate inhibition and allostericity in a subfamily of Xaa-Pro dipeptidases. Biochim Biophys Acta – Proteins Proteomics. 2017; 1865(2):153–64.
- 10. BOZKURT M, YÜKSEL H, EM S, OKTAYOGLU P, YILDIZ M, AKDENIZ D, et al. Serum prolidase enzyme activity and oxidative status in patients with Behçet’s disease. Redox Rep. 2014; 19(2):59–64.
- 11. UÇAR D, EM S, BOZKURT M, OKTAYOGLU P, YÜKSEL HK, ÇAGLAYAN M, et al. Serum Prolidase Activity in Ankylosing Spondylitis and Rheumatoid Arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013; 6: 29–33.
- 12. BASPINAR S, KIRNAP M, BASPINAR O, DIZDAR OS, KOCER D. Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity. Rheumatol Int. 2016; 36(11):1609–16.
- 13. CELIK A, BIRER MN, KILINC M. Serum prolidase activity in systemic sclerosis. Clin Rheumatol. 2017; 36(8):1827–32.
- 14. GUMUS S, YAMAN H, OZCAN O, DENIZ O, KARAMAN B, CAKIR E, et al. Serum prolidase activity in patients with pulmonary tuberculosis. Scand J Clin Lab Invest. 2011; 71(6):467–72.
- 15. YANG Z-C, LIU Y. Hypoxia-Inducible Factor-1α and Autoimmune Lupus, Arthritis. Inflammation. 2016; 39(3):1268–73.
- 16. BRUNO A, HABIB A, HUA S, DIAS TH. Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis. Front Pharmacol Front Pharmacol. 2016; 7:18.